

Special Issue

New Insights and Latest Advances in Corneal and Ocular Surface Diseases

Message from the Guest Editors

Dear colleagues, In recent years, there have been great gains in diagnosing and managing corneal and ocular surface diseases. Our understanding of such conditions has also progressed significantly, from the infinitesimal molecular aberrations that underpin them to the large-scale epidemiological patterns that occur. This Special Issue aims to bring together the latest research evidence on these diseases across disciplines. As such, we invite high-quality submissions of original research and review articles on the prevention, diagnosis, and management of corneal and ocular surface diseases and pathobiology. Submissions from across disciplines, including laboratory, clinical and population health-based research, are welcome. Through a multidisciplinary approach, this Special Issue aims to support a fuller understanding of corneal and ocular surface diseases and ultimately improve patient outcomes through evidence-based practice. Drs Isabella Cheung and Akilesh Gokul

Guest Editors

Dr. Isabella M. Y. Cheung

Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand

Dr. Akilesh Gokul

Department of Ophthalmology, University of Auckland, Auckland 1023, New Zealand

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/198449

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).